DISCOUNT ZERTIFIKAT - ROCHE GS Share Price

Certificat

DE000VU2XVU0

Market Closed - Deutsche Boerse AG 18:53:48 14/06/2024 BST
259.8 EUR +1.31% Intraday chart for DISCOUNT ZERTIFIKAT - ROCHE GS
Current month+10.25%
1 month+13.54%
Date Price Change
14/06/24 259.8 +1.31%
13/06/24 256.5 +1.80%
12/06/24 251.9 +0.43%
11/06/24 250.8 +0.75%
10/06/24 249 -0.53%

Delayed Quote Deutsche Boerse AG

Last update June 14, 2024 at 06:53 pm

More quotes

Static data

Product typeDiscount-Zertifikate
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VU2XVU
ISINDE000VU2XVU0
Date issued 03/02/2023
Maturity 21/06/2024 (6 Days)
Parity 1 : 1
Emission price 251
Emission volume N/A
Settlement Beides
Currency EUR

Technical Indicators

Highest since issue 263.5
Lowest since issue 219.6

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.6 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.30%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW